RIA Advisory Group LLC Buys 35,841 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

RIA Advisory Group LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4,531.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 36,632 shares of the company's stock after acquiring an additional 35,841 shares during the quarter. IDEXX Laboratories makes up 5.9% of RIA Advisory Group LLC's investment portfolio, making the stock its 5th largest position. RIA Advisory Group LLC's holdings in IDEXX Laboratories were worth $20,333,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. OFI Invest Asset Management purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $25,000. Valley National Advisers Inc. raised its holdings in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company's stock valued at $26,000 after acquiring an additional 22 shares in the last quarter. Altshuler Shaham Ltd purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $26,000. Geo Capital Gestora de Recursos Ltd purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $28,000. Finally, Covestor Ltd raised its holdings in shares of IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company's stock valued at $29,000 after acquiring an additional 28 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. William Blair reaffirmed an "outperform" rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the company an "overweight" rating in a research report on Tuesday, February 6th. Piper Sandler lowered IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price objective on the stock. in a research report on Tuesday, January 30th. Barclays increased their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a research report on Tuesday, February 6th. Finally, The Goldman Sachs Group increased their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a research report on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $591.50.

Insider Transactions at IDEXX Laboratories

In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, SVP George Fennell sold 8,198 shares of the firm's stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares of the company's stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 0.3 %

IDXX traded down $1.44 on Friday, hitting $476.35. 568,637 shares of the company were exchanged, compared to its average volume of 429,223. The firm has a fifty day simple moving average of $538.02 and a two-hundred day simple moving average of $508.81. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock has a market capitalization of $39.56 billion, a PE ratio of 47.30, a price-to-earnings-growth ratio of 3.68 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $2.05 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.